Evaluation of osimertinib for advanced non-small cell lung cancer with leptomeningeal metastases: a cost-effectiveness and budget impact analysis

2021 ◽  
Author(s):  
Shaohong Luo ◽  
Xiuhua Weng ◽  
Shen Lin ◽  
Xiaoting Huang ◽  
Lingning Huang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cost Effectiveness ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Impact Analysis ◽  
Budget Impact ◽  
Small Cell ◽  
Leptomeningeal Metastases ◽  
Budget Impact Analysis ◽  
Small Cell Lung

scholarly journals PCN124 BUDGET IMPACT ANALYSIS OF IMMUNOTHERAPY AS SECOND-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) AT MEXICO´S NATIONAL INSTITUTE OF CANCER

2019 ◽  
Vol 22 ◽  
pp. S459-S460
Author(s):  
F. Barrón-Barrón ◽  
A.A. Meneses-García ◽  
L.M. Rivera ◽  
J. de la Garza-Salazar ◽  
A.F. Cardona ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Impact Analysis ◽  
Budget Impact ◽  
Small Cell ◽  
Budget Impact Analysis ◽  
Line Treatment ◽  
Second Line ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document